Participants must be adults aged 1875 with moderately to severely active UC confirmed by endoscopy and histology, having at least 15 cm disease extent from anal verge, modified MS of 59 points with MES of at least 2, and inadequate response or intolerance to prior treatments including corticosteroids, immunomodulators, or advanced therapies, while excluding those with CD, toxic megacolon, prior vedolizumab exposure, or contraindicated medications, with the study completing primary outcomes in October 2025 and final completion estimated for February 2027
PlexusDx partners with licensed compounding pharmacies that provide clear guidance on baseline testing and follow-up schedules
Getting reconstitution right for nasal research applications is not optional
In effect, anti Ken-ergy
Though it prolongs the QT interval, its uniform effect lowers the risk of torsades de pointes, even in susceptible individuals (39)
This can cost up to 95 percent less than it would be to test at a lab